Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

MAR-AMLODIPINE

Canada Type I Ongoing · initiated 2026-02-09

Product safety. Immediately check your medication bottle to ensure it only contains MAR-Amlodipine 5 mg tablets.MAR-Amlodipine 5 mg tablets are white to off-whi…

CEFAZOLIN FOR INJECTION, USP

Canada Type III Ongoing · initiated 2026-02-09

Labelling. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

TARO-CANDESARTAN

Canada Type II Ongoing · initiated 2026-02-09

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

SOMERSET THERAPEUTICS LLC

US Class II Ongoing · initiated 2026-02-04

Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs …

Annora Pharma Private Limited

US Class III Ongoing · initiated 2026-02-03

Presence of foreign tablets/capsules: one Pitavastatin tablet 1mg found in bottle of Pitavastatin tablets 2mg

Pro Numb Tattoo Numbing Spray LLC

US Class II Ongoing · initiated 2026-02-02

cGMP deviations

Pro Numb Tattoo Numbing Spray LLC

US Class II Ongoing · initiated 2026-02-02

cGMP deviations

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-01-29

Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-01-29

Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-01-29

Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-01-29

Failed Dissolution Specifications

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2026-01-27

Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

Granules Pharmaceuticals Inc.

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign Tablets/Capsules

F.H. INVESTMENTS, Inc. (dba Asteria Health)

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health)

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health)

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health)

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health)

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health)

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health)

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign substance - potential presence of metal particulate matter